A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

Inclusion Criteria

• •Have histologically or cytologically confirmed squamous NSCLC.
• •Have stage IV disease at the time of study entry (American Joint Committee on Cancer \[AJCC\] Staging Manual, 7th edition).
• •Have measurable disease at the time of study enrollment as defined by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).
• •Have tumor tissue available for biomarker analysis.
• •Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
• •Have adequate organ functions.
• •Have undergone major surgery or received any investigational therapy in the 4 weeks prior to study entry.
• •Have undergone systemic radiotherapy within 4 weeks prior to study entry, or focal radiotherapy within 2 weeks prior to study entry.
• •Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not required).
• •Have a history of arterial or venous embolism within 6 months prior to study entry.
• •Have clinical evidence of concomitant infectious conditions.
• •Have a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other contraindication to one of the administered treatments.
• •Are pregnant or breastfeeding.
• •Have a known history of drug abuse.
• •Have a concurrent active malignancy. Participants with a history of malignancy are eligible provided the participant has been disease-free for ≥3 years, with the following exception: Participants with adequately treated basal or squamous cell carcinoma of the skin, preinvasive carcinoma of the cervix, or any cancer that in the judgment of the investigator and Lilly clinical research physician/designee may not affect the interpretation of results (for example, prostate, bladder) are eligible.
• •Have discontinued investigational product or non approved use of a drug or device from a clinical trial within 30 days before the first day of study treatment.